

Alternate Day Statin and Fibrate Given Alone or in Combination for Postprandial Dyslipidemia in Patients with Type 2 Diabetes Mellitus: A Preliminary Report



Sheila Farisha K. Mangelen, M.D.¹,
Erick S. Mendoza, M.D.² and
Leilani B. Mercado-Asis, M.D.³

ABSTRACT

Introduction Postprandial lipemia represent an important risk factor for lifetime development of cardiovascular disease in patients with type 2 diabetes mellitus. Daily administration alone or combined statin and fibrate therapy has been shown to be an effective therapeutic approach but brings about serious logistics problem in our local setting. To address this concern, we report this observation where alternate day statin and fibrate treatment given alone or in combination in type 2 diabetes mellitus and

similar effectiveness in lowering postprandial dyslipidemia has been obtained.

Methodology This is a retrospective case study in an endocrine clinic involving 53 patients seen from April 2014 to October 2015. The patients were on statin and fibrate combination (atorvastatin 20-40mg and gemfibrozil 300-600 mg or fenofibrate 145-160mg), statin alone (atorvastatin 20-40mg) and fibrate alone (gemfibrozil 300-600mg/fenofibrate 145-160mg) given on alternate days. Percent reductions of cholesterol, triglycerides, LDL for combined statin and fibrate; cholesterol and LDL for atorvastatin alone; and triglyceride for fibrate alone were determined.

Results In this preliminary report, 26 patients have available data. Follow-up period range was 4 to 48 weeks (mean 22.76 ± 11.8 weeks). Alternate statin and fibrate (gemfibrozil) treatment yielded percent reductions from baseline as follows: cholesterol 7%, triglycerides 15%, and LDL 37% (P values= 0.02, 0.10 and 0.019, respectively). On the other hand, alternate statin and fibrate (fenofibrate) yielded percent reduction from baseline as follows: cholesterol 41% and LDL 20.4% (P=0.15 and 0.13, respectively). The population is small, the decrease did not

✉ Sheila Farisha K. Mangelen
shei_risha@yahoo.com

- ¹ Principal author, Fellow-in-Training, Section of Endocrinology, Diabetes and Metabolism of the Department of Medicine, University of Santo Tomas Hospital, Manila, Philippines
- ² Co-author and Consultant, Section of Endocrinology, Diabetes and Metabolism of the Department of Medicine, University of Santo Tomas Hospital, Manila, Philippines
- ³ Senior Author and Consultant, Section of Endocrinology, Diabetes and Metabolism of the Department of Medicine, University of Santo Tomas Hospital, Manila, Philippines

yield significant difference from baseline, however there is a tendency for triglyceride to decrease ($P=0.09$) with the combined statin and fenofibrate. With statin alone the percent reduction from baseline were as follows: cholesterol 39% and LDL 62% ($P=0.29$ and 0.11 , respectively). No percent reduction of triglyceride is seen with fibrate given on alternate day with $P=0.19$. The monthly cost reduction with combined alternate statin and fibrate treatment is at 34-48% while alternate day administration of the statin reduced cost by 60%.

Conclusion This study showed lowering of postprandial total cholesterol, triglyceride and LDL with alternate statin and fibrate treatment, and total cholesterol and LDL with alternate day statin. The cost of treatment was also significantly lowered with the alternate regimen. However, a follow through study with adequate sample size is recommended to support these observations.

Key words statin, fibrate and postprandial dyslipidemia

INTRODUCTION

Dyslipidemia is a risk factor for atherosclerotic heart disease. It also predisposes to type 2 diabetes mellitus (T2DM) and forms a part in the development of metabolic syndrome. Much of the studies have been focused now on the postprandial metabolic abnormality as a contributory cause of cardiovascular disease in T2DM and in other conditions associated with insulin resistance (1). In fact, postprandial lipemia represent a novel risk factor for vascular disease in people with or without T2DM. Among Filipinos, median time for postprandial lipemia peak (for cholesterol, triglycerides (TG), high density lipoprotein (HDL)) is at 4th to 5th hour (2). Abnormal increase in postprandial dyslipidemia has been attributed to exaggerated response of postprandial triglyceride-rich lipoproteins (TRL) and accumulation of cholesterol-rich remnant (3). The increase of TRL in the circulation has adverse effects on the metabolism of both low density lipoprotein (LDL) and HDL species as well as on the arterial wall. TRL particles may be directly trapped to vessel wall and cause endothelial dysfunction and oxidative stress (4). Therefore, excessive postprandial lipemia may be a more important contributor to CHD risk than can be assumed from triglyceride values alone. Postprandial

hypertriglyceridemia can be a good marker for cardiovascular outcome because it can be an independent risk factor for early atherogenesis in T2DM. Along with aggressive control of postprandial hyperglycemia is the aggressive control of postprandial lipemia to prevent microvascular and macrovascular complications (5).

There are numerous studies on statin and fibrates therapy given alone or in combination therapy. These studies have shown the effectiveness of statin and fibrate alone or in combination in lowering lipids while avoiding rhabdomyolysis. In some, combination therapy is needed in individuals who have established T2DM, a cardiovascular equivalent where statin alone cannot adequately control the postprandial lipemia (6). While researchers have found a way to treat the dyslipidemia with above mentioned medications, another challenge faced is the cost. One way to reduce cost and at the same time addressing dyslipidemia including postprandial dyslipidemia is by alternating the statin and fibrates to achieve the lipid profile values within range (7). This study aims to provide a preliminary report on the effectiveness of alternate statin and fibrate give alone or in combination in lowering postprandial dyslipidemia. The initial design and results of this study will be used to conduct a follow through study with larger population involved.

PATIENTS AND METHODS

Study Design and Population

Fifty three ($N=53$) charts of patients seen April 2014 to October 2015 were retrieved and reviewed from an endocrine clinic after securing Institutional Review Board (IRB) approval from University of Santo Tomas Hospital (USTH) (IRB-2016-06-111-TF). Twenty-six ($n=26$) fulfilled the inclusion criteria. Retrospective case study of the eligible subjects was conducted.

The sample size was based on the number of patients who are on alternate statin and fibrate combination or on statin or fibrate given alone on alternate days seen within the study period. Subjects included in the study were: ≥ 18 y.o. with T2DM and hypertension, with baseline and follow up lipid profile (cholesterol, triglyceride, HDL and LDL) and on alternate statin (atorvastatin 20 to 40mg), and fibrate therapy (gemfibrozil 300 to 600 mg and fenofibrate 145-160 mg) given alone or in combination. Patients

with baseline lipid profile but no follow up were excluded from the study.

Outcome measures were: mean difference of baseline and follow up cholesterol, triglycerides, LDL for alternate day combined statin and fibrate treatment; mean difference of baseline and follow up cholesterol and LDL for alternate day statin given alone; mean difference of baseline and follow up triglyceride for alternate day fibrate given alone; and monthly cost difference of the alternate day and daily statin/fibrate or combination treatment.

Statistical analysis

The mean difference of the cholesterol, triglyceride, HDL and LDL at baseline and on most recent follow up were obtained. Data was analyzed using the T-test with percent reduction considered significant at P value <0.05.

RESULTS

Fifty-three charts were retrieved from April 2014 to October 2015, 26 of which were included in the study population. Follow-up period range was 4-48 weeks (22.76+ 11.8 weeks). Of the 26 patients, 13 patients were on combination atorvastatin 20-40mg and gemfibrozil 300-600 mg, 3 on combination atorvastatin 20-40mg and fenofibrate 145-160mg, 6 on gemfibrozil 300-600mg 2x a day, 1 on fenofibrate 160 mg and 3 on atorvastatin 40 mg.

The population in this study are mostly elderly, 35 of which are female and 18 were male as shown in Table 1. Mean age of the patients is 59.5+ 12.39. Baseline weight was 63.9+32.6 kg and baseline height was 154.8+14.2 cm. Thirty-two percent of patients were obese I, 28% were overweight while 16% was Obese II. Most of the patients included in

the study have good to poorly controlled T2DM with baseline Hba1c at 7.5+5.02.

Baseline values of cholesterol, triglycerides, HDL and LDL were compared with the follow up values. Emphasis on changes in cholesterol, LDL and triglycerides for combined statin and fibrate, cholesterol and LDL for statins given alone, triglycerides for fibrate given alone on alternate days. Changes in the values were expressed as differences and the mean differences of the values were derived.

The mean differences of the lipid profiles from baseline to follow up are shown in Table 2 to 4. Table 2 shows the alternate atorvastatin and gemfibrozil combination effect on the lipid levels. The percent reductions were 7% for cholesterol, 15% for triglyceride and 37% for LDL. Reduction was significant with P values at 0.02 and 0.019 for cholesterol and LDL respectively with use of the alternate day combination atorvastatin and gemfibrozil. The percent reduction in LDL is comparable to the study made Natarajan et al. wherein the LDL was reduced by 39.2%

Table 1. Profile of patients whose charts are available for review.

Profile	Value
Study Population (N)	53
Age (years)	59.5+ 12.39
Female	35
Male	18
BMI (kg/m ²) ^{a,b}	26.72+14.9
Actual weight, kg	63.9+32.6
Actual height, cm	154.8+14.2
Obese I	17/53 (32%)
Obese II	9/53 (16%)
Overweight	15/53 (28%)
Hba1c (%)	7.5+5.02

^a WHO-Asia Pacific Classification of Obesity

^b Normal Range: 18.5-22.9

Table 2. Mean differences, percent reduction and P values of lipids from baseline to follow up with alternate day combined statin and fibrate (gemfibrozil) treatment

	Cholesterol	Triglyceride	HDL	LDL
Mean Difference	16	31.3	1.46	15.5
Mean baseline	217	207.30	30.60	150.90
Mean follow up	199.9	154.36	30.7	85
% Reduction from baseline	7	15	5	37
P value ^a	0.02	0.10	0.04	0.019

^a P value < 0.05 - statistically significant using T-test

Table 3. Mean differences, percent reduction and P values of lipids from baseline to follow up with alternate day combined statin and fibrate (fenofibrate) treatment

	Cholesterol	Triglyceride	HDL	LDL
Mean Difference	59.41	-32.14	-6.05	7.78
Mean baseline	145.54	181.35	45.64	56.32
Mean follow up	86.35	213.49	47.98	60.2
% Reduction from baseline	41	-17	-13	20.4
P value ^a	0.15	0.09	0.4	0.13

^a P value < 0.05 - statistically significant using T-test

Table 4. Mean differences, percent reduction and P values of lipids from baseline to follow up with fibrate (gemfibrozil) given alone on alternate days

	Cholesterol	Triglyceride	HDL	LDL
Mean Difference	-36.1	-58.62	-9.62	-26.03
Mean baseline	167.83	194.3	234.16	35.5
Mean follow up	185.25	270.50	31.45	100.09
% Reduction from baseline	-21.7	-30	-4.1	-73
P value ^a	0.028	0.19	0.37	3.12

^a P value < 0.05 - statistically significant using T-test

Table 5. Mean differences, percent reduction and P values of lipids from baseline to follow up with statin given alone on alternate days.

	Cholesterol	Triglyceride	HDL	LDL
Mean Difference	65.6	-46.7	24.5	69
Mean baseline	167.6	80.9	52	110.46
Mean follow up	143.3	59	46	92
% Reduction from baseline	39.14	57	47	62
P value ^a	0.29	0.08	0.05	0.11

^a P value < 0.05 - statistically significant using T-test

Table 3 shows percent reduction of cholesterol and LDL with alternate atorvastatin and fenofibrate treatment. Reduction was 41% and 20.4%, respectively.

Table 4 shows no percent reduction in the triglycerides when the gemfibrozil 300-600mg 2x a day was given on alternate days. For the atorvastatin 20-40mg tablet given alone on alternate days, the cholesterol was reduced by 39% from baseline and LDL reduced by 62%. There was only 1 patient on fenofibrate 160 mg tablet once a day. The triglyceride value of this patient at baseline 40mg/dl and 98mg/dl on follow up. Although the values increased it is within the normal range (35-199mg/dl).

Monthly cost difference of combined daily atorvastatin and gemfibrozil with the alternate day regimen is P805.92 corresponding to 48% cost

reduction. When given on alternate basis not only is the cholesterol, triglycerides and LDL reduced but also the price which is reduced to almost half. In the combined daily atorvastatin and fenofibrate with the alternate day regimen monthly cost difference is P948.48 at 34% cost reduction. Alternate day administration of the statin reduced cost by 60%. This is very important in health economics standpoint where most cannot maintain the drugs on daily basis because of the cost.

DISCUSSION

A. Pharmacokinetics of Drugs Used

Atorvastatin used in this study is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.

Its inhibition of the HMG-Coa reductase upregulates the LDL receptors in the cell membrane resulting to clearance of the LDL in the blood. A 20 mg and 40 mg dose of atorvastatin alone can lower the LDL by 43% and 48% respectively (8). Aside from the LDL which is the major lipoprotein lowered by statins, triglyceride is also reduced by 10 to 33% and HDL is increased by 5 to 10% (9). Half-life of atorvastatin is 11-24 hours. Its LDL lowering effect duration is longer than its pharmacokinetic half-life making it efficacious even if given on an alternate day basis. The LDL reduction is comparable with daily and alternate day statin administration. With this same efficacy, cost savings is evident at same time lowering incidences of myalgias on patients.

The gemfibrozil and fenofibrates are both used in this study. The effects of fibrates on lipids are mediated by activation of the peroxisome proliferator-activated receptors (PPARs), transcription factors belonging to the nuclear hormone receptor superfamily. Gemfibrozil lowers the triglyceride by 35 to 50% also acts to reduce the LDL by 10 to 15 % and increase the HDL by 5-20% from the baseline (10). Gemfibrozil has a half-life of 1.5 hours. It can increase the concentration of atorvastatin when given in combination. Fenofibrates lowers the triglycerides by 41-53% and has half-life of 14-35 hours. There was only one patient on fenofibrate 160mg tablet once a day given on alternate day included in the study, hence it is inconclusive whether this regimen can reduce the triglyceride significantly.

B. The importance of treating Combined Postprandial Dyslipidemia

Fasting lipid concentration similar with fasting glucose does not reflect postprandial state which is characterized by increased in concentrations of glucose and lipids. Postprandial hyperglycemia and lipemia cause oxidative stress triggering events such as inflammation, endothelial dysfunction, hypercoagulability and sympathetic hyperactivity. Both parameters are related since both result to vascular changes. Patients with postprandial elevation of triglycerides are found to have increased carotid intima media thickness.

Combination treatment with statin and fibrate is indicated in high risk patients with combined dyslipi-

demia not controlled with monotherapy or patients who are completely intolerant to statins. High risk patients include those with atherosclerotic cardiovascular disease (ASCVD), those with LDL-C \geq 190 mg/dL and individuals with diabetes (11). All subjects in this study are diabetics and at the same time hypertensive. Twenty-four weeks' study comparing atorvastatin and gemfibrozil alone and in combination treatment showed that combination treatment given daily is superior to monotherapy. Combined treatment lowered the LDL and triglyceride by 26.5% and 24.1% respectively (12). As compared to our study conducted, alternate statin and fibrate treatment with same drugs lowered the LDL by 7% and the triglyceride by 15%. The percent reduction is lower and this may be due to the small sample size (n=26).

C. Cost- effectiveness of Alternate Treatment with Statin and Fibrate Alone or in Combination

In terms of the monthly expenses, the alternate treatment regimen reduces cost by 34 to 48% in reference to the current price of the agents used in this study (13). The cost is a considerable issue here since most of patients in our practice are unable to sustain a higher price of drugs for their daily maintenance treatment.

CONCLUSION

Our preliminary report showed lowering of postprandial total cholesterol, LDL-cholesterol and triglyceride with alternate atorvastatin and gemfibrozil combination and atorvastatin alone regimen. There is also change in the cholesterol and LDL with atorvastatin and fenofibrate combination given on alternate days. Most importantly, we have significantly lowered the cost of treatment by 34-48%.

LIMITATION OF THE STUDY

The sample size in this study is small. A follow through study with recruitment of more patients is ideal to obtain satisfactory results.

CONFLICT OF INTEREST

The authors have no conflict of interest in this study.

ACKNOWLEDGEMENTS

This research work was completed with the help of our research assistant, Ms. Jacquelin Ombac and clinic secretary Ms. Shirley dela Rosa.

REFERENCES

1. Nasser Hissa MR, Cavalcante LL, Guimarães SB, Nasser Hissa M. A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Diabetol Metab Syndr*. 2015 Jul 11;7:62.
2. So T, Mercado-Asis LB, Zacarias M. A Comparison of Dose Response Postprandial Lipid Profile of Health Filipino Subjects After an Oral Fat Challenge Test of Varying Fat Contents. *PJIM*. Jan-Feb 2004. 42:1-7.
3. Matikainen N, Manttari S, Westerbacka J, Vehkavaara S, Lundbom N, Yki-Jarvinen H, Taskinen MR. Postprandial Lipemia Associates with Liver Fat Content. *J Clin Endocrinol Metab*. 2007 Aug;92(8):3052-9.
4. Castro-Caringal JA, Mendoza ES, Mercado-Asis LB. Postprandial Lipemia is significantly Correlated with Postprandial Hyperglycemia and Poor Glycemic Control among Patients with Type 2 Diabetes Mellitus. *PJIM*. October-December 2015. Vol 53 (4). pp1-3
5. Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, Hou R, Qin Y. Meta-Analysis of Safety of the Coadministration of Statin With Fenofibrate in Patients With Combined Hyperlipidemia. *Am J Cardiol*. 2012 Nov 1;110(9):1296-301
6. Samson CE, Galia A, Llave KI, Zacarias MB, Mercado-Asis LB. Postprandial Peaking and Plateauing of Triglycerides and VLDL in Patients with Underlying Cardiovascular Diseases despite Treatment. *Int J Endocrinol Metab*. 2012; 10(4):587-593
7. Harivenkatesh N, David DC, Haribalaji N, Sudhakar MK. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. *J Cardiovasc Pharmacol Ther*. 2014 May;19(3):296-303.
8. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Structural mechanism for statin inhibition of HMG-CoA reductase. *Science*. 2001;292(5519):1160
9. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation*. 1998;98(19):2088
10. Melmed S, Polonsky K, Larsen P, Kronenberg H, Williams Textbook of Endocrinology. 12th Edition. 2011. p1664
11. Stone NJ et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. 2013. p45
12. Wagner AW, Jorba O, Bonet R, Ordonez-Llanos J, and Perez A. Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia. *J Clin Endocrinol Metab*. 2003 Jul;88(7):3212-7
13. Ping NH, Lim C, Dela Pena LA, Tamolang SE. *MIMS*. 143rd Edition. 2015. p122,130



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.